Status:
COMPLETED
Composite Probiotics Stabilize Lipid Metabolism in Chronic Hepatitis B Patients:A Clinical Trial
Lead Sponsor:
Wecare Probiotics Co., Ltd.
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV infection levels and regulating intestinal flora in patients with chronic hepatitis B. The main question it ...
Eligibility Criteria
Inclusion
- Meet the hepatitis B clinical diagnostic criteria of the Chronic Hepatitis B Prevention and Treatment Guidelines (2022 edition), excluding patients infected with hepatitis C virus, hepatitis D virus and other hepatitis viruses;
- Be aware of the content and purpose of this study, and voluntarily sign the treatment study consent.
Exclusion
- Patients infected within 3 months;
- Received antibiotic treatment within 3 months;
- Received probiotic and probiotic therapy within 3 months;
- Complicated with hypertension or diabetes;
- Obesity or significantly low weight;
- Obvious atherosclerosis;
- Chronic kidney disease;
- Inflammatory bowel disease, irritable bowel syndrome, or a history of gastrointestinal surgery;
- Malignant tumors;
- Autoimmune diseases;
- Mental illnesses such as Parkinson's disease, Alzheimer's disease and stroke;
- Pregnant or lactating women;
- Patients with cirrhosis or decompensated liver disease;
- Subjects cannot participate in the experiment due to their reasons; Those who meet any of the above criteria will not be selected.
Key Trial Info
Start Date :
March 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 11 2025
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06221605
Start Date
March 30 2024
End Date
April 11 2025
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital Affiliated with Fudan University
Shanghai, Shanghai Municipality, China, 200000